OBJECTIVES: The aim of this pilot study was to assess post-treatment apparent diffusion coefficient (ADC) changes of diffuse large B-cell lymphoma lesions on respiratory-gated whole-body diffusion-weighted imaging (DWI), with integrated (18)F-fluoro-2-deoxyglucose positron emission tomography/computed tomography (PET/CT) as the reference standard. MATERIALS AND METHODS: A total of 15 patients underwent both whole-body DWI (b = 50, 400, 800 s/mm(2)) and PET/CT before initiation and after 4 cycles of chemotherapy. ADC of residual masses (lymph node and organ lesions) was assessed both visually and quantitatively, including measurement of mean ADC (ADC).(Figure is included in full-text article.) RESULTS: After chemotherapy, among 85 examined lymph node regions, residual nodes were present in 62 (73%) regions on DWI. Of these 62 regions, 26 had persistent lymph nodes with longest transverse diameter >10 mm, ie, positive based on DWI size criteria. The mean ADC of these 26 regions increased from 0.658 × 10(-3) ± 0.153 mm(2)/s (standard deviation) at baseline to 1.501 × 10(-3) ± 0.307 mm(2)/s (paired t test, P < 0.0001). Only 6 of these 26 regions were considered positive on PET/CT. Combining visual ADC analysis to size criteria reduced the number of false-positive results of DWI from 20 to 2 regions. For organ involvement, ADC values also increased compared with baseline (1.558 × 10(-3) ± 0.424 mm(2)/s vs. 0.675 × 10(-3) ± 0.135 mm(2)/s, respectively; P = 0.0009). CONCLUSIONS: Whole-body DWI with ADC mapping can show a significant increase in ADC values of residual masses persisting after treatment and may help to assess the treatment response in patients with diffuse large B-cell lymphoma.
OBJECTIVES: The aim of this pilot study was to assess post-treatment apparent diffusion coefficient (ADC) changes of diffuse large B-cell lymphoma lesions on respiratory-gated whole-body diffusion-weighted imaging (DWI), with integrated (18)F-fluoro-2-deoxyglucose positron emission tomography/computed tomography (PET/CT) as the reference standard. MATERIALS AND METHODS: A total of 15 patients underwent both whole-body DWI (b = 50, 400, 800 s/mm(2)) and PET/CT before initiation and after 4 cycles of chemotherapy. ADC of residual masses (lymph node and organ lesions) was assessed both visually and quantitatively, including measurement of mean ADC (ADC).(Figure is included in full-text article.) RESULTS: After chemotherapy, among 85 examined lymph node regions, residual nodes were present in 62 (73%) regions on DWI. Of these 62 regions, 26 had persistent lymph nodes with longest transverse diameter >10 mm, ie, positive based on DWI size criteria. The mean ADC of these 26 regions increased from 0.658 × 10(-3) ± 0.153 mm(2)/s (standard deviation) at baseline to 1.501 × 10(-3) ± 0.307 mm(2)/s (paired t test, P < 0.0001). Only 6 of these 26 regions were considered positive on PET/CT. Combining visual ADC analysis to size criteria reduced the number of false-positive results of DWI from 20 to 2 regions. For organ involvement, ADC values also increased compared with baseline (1.558 × 10(-3) ± 0.424 mm(2)/s vs. 0.675 × 10(-3) ± 0.135 mm(2)/s, respectively; P = 0.0009). CONCLUSIONS: Whole-body DWI with ADC mapping can show a significant increase in ADC values of residual masses persisting after treatment and may help to assess the treatment response in patients with diffuse large B-cell lymphoma.
Authors: Michael A Jacobs; Katarzyna J Macura; Atif Zaheer; Emmanuel S Antonarakis; Vered Stearns; Antonio C Wolff; Thorsten Feiweier; Ihab R Kamel; Richard L Wahl; Li Pan Journal: Acad Radiol Date: 2018-04-04 Impact factor: 3.173
Authors: Rui Wu; Shi Teng Suo; Lian Ming Wu; Qiu Ying Yao; Hong Xia Gong; Jian Rong Xu Journal: Diagn Interv Radiol Date: 2017 May-Jun Impact factor: 2.630
Authors: Annemieke S Littooij; Thomas C Kwee; Ignasi Barber; Claudio Granata; Malou A Vermoolen; Goya Enríquez; József Zsíros; Shui Yen Soh; Bart de Keizer; Frederik J A Beek; Monique G Hobbelink; Marc B Bierings; Jaap Stoker; Rutger A J Nievelstein Journal: Eur Radiol Date: 2014-02-23 Impact factor: 5.315
Authors: Marilyn J Siegel; Clint E Jokerst; Dhana Rajderkar; Charles F Hildebolt; Sagun Goyal; Farrokh Dehdashti; Nina Wagner Johnston; Barry A Siegel Journal: NMR Biomed Date: 2014-04-03 Impact factor: 4.044
Authors: Ricardo Donners; Raphael Shih Zhu Yiin; Dow-Mu Koh; Katja De Paepe; Ian Chau; Sue Chua; Matthew D Blackledge Journal: Quant Imaging Med Surg Date: 2021-08
Authors: Katja De Paepe; Charlotte Bevernage; Frederik De Keyzer; Pascal Wolter; Olivier Gheysens; Ann Janssens; Raymond Oyen; Gregor Verhoef; Vincent Vandecaveye Journal: Cancer Imaging Date: 2013-03-05 Impact factor: 3.909